Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04722575
Title Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-risk, Resectable Melanoma (NEO-TIM)
Acronym NEO-TIM
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Fondazione Melanoma Onlus
Indications
Therapies
Age Groups: adult | senior
Covered Countries ITA


No variant requirements are available.